Clinical trials: Pelcitoclax
Neuroendocrine Tumors
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT04893759
- Testing
- Pelcitoclax
- Where
- 3 sites in China
- Volunteers
- 2 people
- Sponsor
- Ascentage Pharma Group Inc.